Loading...
XSTO
GENO
Market cap129mUSD
Jul 09, Last price  
19.00SEK
1D
1.17%
1Q
-4.04%
Jan 2017
645.10%
IPO
-61.18%
Name

Genovis AB

Chart & Performance

D1W1MN
XSTO:GENO chart
P/E
53.42
P/S
9.73
EPS
0.36
Div Yield, %
Shrs. gr., 5y
0.21%
Rev. gr., 5y
16.14%
Revenues
129m
-1.08%
379,653986,1781,596,0192,856,0836,080,8738,912,0938,252,06413,268,50118,541,94122,867,26634,567,98060,549,14161,029,72193,017,543102,386,899158,232,000130,358,000128,946,000
Net income
23m
-28.61%
-27,149,579-17,558,226-11,291,508-13,607,963-19,915,127-15,852,513-22,048,663-19,905,623-15,031,013-7,948,532-1,710,3819,551,5766,445,90224,777,38511,191,00061,500,00032,916,00023,498,000
CFO
32m
-13.72%
-16,760,756-13,695,153-10,484,825-12,149,160-14,847,903-12,467,813-22,192,335-16,117,301-16,075,111-8,355,087-1,249,59513,125,5533,755,19345,918,901-927,94767,752,00037,116,00032,022,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.
IPO date
Nov 11, 2005
Employees
38
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT